Neuraxis (NRXS) Net Cash Flow (2022 - 2025)
Neuraxis (NRXS) posted Net Cash Flow of $587963.0 for Q4 2025, up 136.49% sequentially from -$1.6 million in Q3 2025, and down 82.89% YoY from $3.4 million in Q4 2024.
Neuraxis (NRXS) Net Cash Flow (2022 - 2025) Analysis & Trends
Neuraxis has reported Net Cash Flow for 4 years, with the latest figure at $587963.0 in Q4 2025.
- Quarterly Net Cash Flow fell 82.89% year-over-year to $587963.0 in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $3.0 million (up 53.86% YoY) and the FY2025 annual result came in at $1.3 million, down 64.95% from the prior year.
- Net Cash Flow rose to $587963.0 in Q4 2025 per NRXS's latest filing, from -$1.6 million in the prior quarter.
- Over five years, Net Cash Flow peaked at $4.0 million in Q2 2025 and troughed at -$1.7 million in Q1 2025.
- A 4-year average of $349387.6 and a median of $4584.5 in 2023 frame the typical range for Net Cash Flow.
- The sharpest annual moves came in 2024 and 2025: Net Cash Flow jumped 28066.67% in 2024, then sank 53091.85% in 2025.
- Over 4 years, Net Cash Flow stood at $245879.0 in 2022, then tumbled by 377.65% to -$682689.0 in 2023, then soared by 603.3% to $3.4 million in 2024, then tumbled by 82.89% to $587963.0 in 2025.
- According to Business Quant data, Net Cash Flow over the past three periods registered $587963.0, -$1.6 million, and $4.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Neuraxis | 74.54 Mn | 66.21 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 587,963.00 |
| Dec 31, 2025 | 587,963.00 |
| Sep 30, 2025 | -1.61 Mn |
| Sep 30, 2025 | -1.61 Mn |
| Jun 30, 2025 | 3.98 Mn |
| Jun 30, 2025 | 3.98 Mn |
| Mar 31, 2025 | -1.69 Mn |
| Mar 31, 2025 | -1.69 Mn |
| Dec 31, 2024 | 3.44 Mn |
| Dec 31, 2024 | 3.44 Mn |
| Sep 30, 2024 | -1.50 Mn |
| Sep 30, 2024 | -1.50 Mn |
| Jun 30, 2024 | 1.68 Mn |
| Jun 30, 2024 | 1.68 Mn |
| Mar 31, 2024 | 3,192.00 |
| Mar 31, 2024 | 3,192.00 |
| Dec 31, 2023 | -682,689.00 |
| Dec 31, 2023 | -682,689.00 |
| Sep 30, 2023 | 709,809.00 |
| Sep 30, 2023 | 709,809.00 |